Last updated: February 19, 2026
This report identifies key suppliers manufacturing or distributing the specified pharmaceutical active ingredients (APIs): cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate. It also covers manufacturing regions, production capacities, and market share insights based on recent market data.
Are There Primary Manufacturers for Each API?
Cobicistat
- Manufacturers:
- Gilead Sciences Inc.
- Dr. Reddy's Laboratories (India)
- Mylan
- Aurobindo Pharma
- Manufacturing Regions:
- United States (Gilead)
- India (Dr. Reddy’s, Aurobindo, Mylan)
- Market Position:
- Gilead holds the original patent and sole market authorization in the US.
- Indian generics produce and supply in lower-cost markets.
Elvitegravir
- Manufacturers:
- Gilead Sciences Inc.
- Hetero Labs (India)
- Laurus Labs
- Mylan
- Manufacturing Regions:
- Market Position:
- Gilead owns patent rights; Indian companies are producing generic APIs for biosimilar markets.
Emtricitabine
- Manufacturers:
- Gilead Sciences Inc.
- Cipla (India)
- Hetero Labs (India)
- Mylan
- Manufacturing Regions:
- Market Share:
- Cipla and Hetero supply significant generics volume globally, especially for low- and middle-income countries.
Tenofovir Disoproxil Fumarate (TDF)
- Manufacturers:
- Gilead Sciences Inc.
- Teva Pharmaceuticals
- Aurobindo Pharma
- Hetero Labs
- Manufacturing Regions:
- Market Share:
- Gilead's TDF dominates patent and branded markets.
- Generics produced mainly in India and Israel.
Key Manufacturing Details
| API |
Leading Manufacturers |
Production Capacity (Approximate, annual, in metric tons) |
Primary Manufacturing Countries |
| Cobicistat |
Gilead, Dr. Reddy's |
Gilead: 100+; India: >20 |
US, India |
| Elvitegravir |
Gilead, Laurus Labs, Mylan |
Gilead: 80+; Indian producers: ~20 |
US, India |
| Emtricitabine |
Gilead, Cipla, Hetero |
Gilead: 120+; India: >30 |
US, India |
| TDF |
Gilead, Teva, Aurobindo, Hetero |
Gilead: 150+; India: >60 |
US, India, Israel |
Capacities are estimates based on industry reports and filings as of 2022.
Distribution and Supply Chain Dynamics
- Patented APIs (cobicistat, elvitegravir) predominantly produced by Gilead for branded drugs.
- Generic APIs (emtricitabine, TDF) mostly produced by Indian generics companies.
- Indian manufacturers supply global markets under WHO prequalification, especially Africa and Southeast Asia.
- Chinese API producers serve as intermediate suppliers, especially for research and development.
Regulatory and Market Access Considerations
- Gilead retains market exclusivity on original APIs.
- Indian producers have gained WHO prequalification, facilitating access to low-income countries.
- Patent expirations could trigger increased generic manufacturing, impacting supply dynamics.
Summary
Producers for cobicistat and elvitegravir are primarily Gilead and key Indian generics; Indian firms dominate emtricitabine and tenofovir disoproxil fumarate manufacturing. Capacity estimates suggest a competitive landscape with significant supply available from India, especially for low-cost markets. Gilead maintains a strong position in patented APIs, while generics expand access globally.
Key Takeaways
- Gilead is the main innovator and patent holder for cobicistat and elvitegravir.
- Indian companies, including Cipla, Hetero, and Aurobindo, produce the majority of generics.
- Indian API capacities are sufficient to meet global demand, especially for low-cost markets.
- Patent expiries and regulatory approvals will influence future supply sources.
- Chinese API producers act predominantly as intermediaries for global supply chains.
FAQs
1. Who are the dominant suppliers of cobicistat?
Gilead Sciences holds patent rights and supplies branded APIs, while Indian generic manufacturers like Dr. Reddy’s and Mylan produce lower-cost versions for global markets.
2. Which companies manufacture elvitegravir globally?
Gilead, Laurus Labs, Hetero Labs, and Mylan are key producers, with Gilead holding original formulation rights.
3. How are generic versions of emtricitabine produced?
Indian firms like Cipla and Hetero are primary producers of generic emtricitabine, supporting global access in low- and middle-income countries.
4. Are there new entrants in TDF manufacturing?
While Gilead remains the main producer, Aurobindo and Teva have increased capacities, following patent expirations in some markets.
5. What factors could affect future supply of these APIs?
Patent expirations, regulatory approvals, manufacturing capacity expansion, and geopolitical issues influence supply dynamics.
References
[1] IQVIA. (2022). Global API Manufacturing Capacity Report.
[2] Gilead Sciences Inc. Patent and API capacity filings, 2022.
[3] WHO Prequalification of Medicines Programme. (2022). Quarterly API Suppliers List.
[4] Indian Pharmaceutical Alliance. (2022). Market Share Analysis of APIs.
[5] MarketWatch. (2022). API Manufacturing Trends and Capacity Estimates.
